AP Biosciences

AP Biosciences OCF Margin

The Operating Cash Flow Margin of AP Biosciences (6945.TWO) as of Nov 17, 2026 is -922.75 %. In the previous year, Operating Cash Flow Margin was -2,412.18 % — a change of -61.75% (higher).

OCF Margin

-922.75 %

YoY

-61.75%

Last updated:

Operating Cash Flow Margin of AP Biosciences is 2023 -922.75 % . Operating Cash Flow Margin of AP Biosciences was 2022 -2,412.18 % . It decreases by -61.75% higher compared to the previous year.

The AP Biosciences OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2020
-0.01 TWD
Jan 1, 2021
-2,412.18 TWD
Jan 1, 2023
-922.75 TWD
The AP Biosciences OCF Margin history
YEAROCF MarginYoY
-922.75 %-61.75%
-2,412.18 %+19.47 M%
-0.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AP Biosciences Stock analysis

What does AP Biosciences do? AP Biosciences Inc generates revenue through the development and commercialization of protein and antibody drugs. The company focuses on early-stage drug candidates and preclinical trials, utilizing its technology platforms to create monoclonal and bispecific antibody drugs. Key products include IBI302, OmniMab, AP505, T-cube, and AP203, which target specific disease mechanisms and therapeutic areas. The primary buyers are pharmaceutical companies seeking to expand their drug pipelines through partnerships and licensing agreements. The firm's technology platforms, such as OmniMab fully human antibody library and T-cube, enable the development of novel bispecific antibodies. These platforms support the creation of drugs like AP505-PD-L1 x VEGF bispecific antibody and AP203-PD-L1 x CD137 fully human bispecific antibody, which are designed for specific therapeutic targets. The company's research and development efforts target diseases with high unmet medical needs, attracting interest from potential collaborators in the biopharmaceutical sector. AP Biosciences Inc's business model relies on advancing its pipeline of drug candidates through preclinical and clinical stages, with the goal of securing partnerships or licensing deals with larger pharmaceutical firms. The company's focus on bispecific antibody technology and its proprietary platforms positions it to generate revenue from milestone payments and royalties upon successful development and commercialization of its drug candidates. AP Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AP Biosciences stock

Operating Cash Flow Margin of AP Biosciences is -922.75 % in 2023.

Operating Cash Flow Margin of AP Biosciences changed from -2,412.18 % to -922.75 %, representing a -61.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin AP Biosciences since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's AP Biosciences with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — AP Biosciences

All Key Metrics — AP Biosciences